Alan B. Lancz & Associates, Inc. Grifols Sa Transaction History

Alan B. Lancz & Associates, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$8.91 - $10.91 $7,128 - $8,728	-800 Reduced 5.46%	13,850 $126,000
Q2 2023 Aug 09, 2023	BUY	$7.14 - $9.29 $104,601 - $136,098	14,650 New	14,650 $134,000
Q4 2022 Feb 13, 2023	BUY	$5.96 - $8.53 $87,314 - $124,964	14,650 New	14,650 $124,000
Q2 2022 Aug 11, 2022	BUY	$10.6 - $13.28 $156,880 - $196,544	14,800 New	14,800 $131,000

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.31B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Alan B. Lancz & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Alan B. Lancz & Associates, Inc. with notifications on news.